News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Sonnet BioTherapeutics to present preclinical data on SON-080 for neuropathies at AACR Annual Meeting 2024. The study focuses on safety and clinical plans using recombinant human Interleukin-6 -
-
-
COMMUNIQUÉ DE PRESSE
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Sonnet BioTherapeutics successfully completes Phase 1b trial of SON-080 with positive safety profile, paving the way for Phase 2 trial in Diabetic Peripheral Neuropathy (DPN) after potential partnership -
-
